PARP1 and ovarian carcinoma: Through a previous exploration of the mechanism of drug action of MEnZn‐CuO NPs in ovarian cancer cell lines, we speculated that the synergistic activity of MEnZn‐CuO NPs and PARP inhibitors might be related to HR repair damage.